Skip to main content
Smart Investors Daily
Honeywell International Inc. logo

NYSE · HON

Honeywell International Inc.

Industrials · Conglomerates

$203.44

Up+$2.06 (+1.02%)

Updated Sep 16, 2026, 11:42 AM

SID Score

6.5/10

Composite research score

Smart Money

60/100

Neutral

Market cap
123.08B
P/E ratio
20.09
Dividend yield
2.15%
52-week range
$192.51 – $457.62
Volume
3.69M
Avg. volume
4.62M

Price performance

HON price history

1M range · 0 trading sessions · Daily adjusted prices

HON does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest HON news

The latest Smart Investors Daily articles mentioning HON.

HON research

Overview

Company profile and research snapshot.

Company profile

Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies (37% of 2023 company revenue), industrial automation (29%), energy and sustainability solutions (17%), and building automation (17%). Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around 30% of its revenue from recurring aftermarket services.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$240.71
Implied upside
Analysts
17
HON recent ratings
DateFirmRatingTarget
Aug 31, 2026Morgan StanleyEqual-Weight
Aug 18, 2026RBC CapitalOutperform
Aug 14, 2026JP MorganOverweight
Jul 28, 2026B of A SecuritiesNeutral
Jul 27, 2026MizuhoOutperform
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Ennov Appoints Oxana Pickeral as Chief Executive Officer

PARIS, September 09, 2026--Ennov (the "Company"), a global provider of a unified compliance platform that streamlines regulatory, clinical, quality, and pharmacovigilance operations for life sciences and healthcare companies, today announced the appointment of Dr. Oxana Pickeral as Chief Executive Officer. Founder and outgoing CEO, Olivier Pâris, will join Ennov’s Board of Directors and continue to support the company as a Strategic Advisor.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.